INT209387

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.25
First Reported 2007
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 9
Total Number 10
Disease Relevance 7.61
Pain Relevance 0.90

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

transferase activity, transferring glycosyl groups (Ugcg) Golgi apparatus (Ugcg) lipid metabolic process (Ugcg)
Anatomy Link Frequency
brain 1
decidua 1
Ugcg (Mus musculus)
Pain Link Frequency Relevance Heat
medulla 27 100.00 Very High Very High Very High
Inflammatory response 8 93.08 High High
cva 8 86.72 High High
Dismenorea 1 78.00 Quite High
Inflammation 7 76.88 Quite High
cytokine 3 75.04 Quite High
peripheral neuropathy 10 69.20 Quite High
Inflammatory mediators 1 32.48 Quite Low
antiepileptic Drug 1 23.88 Low Low
Central nervous system 18 13.28 Low Low
Disease Link Frequency Relevance Heat
Brain Death 47 100.00 Very High Very High Very High
Fabry Disease 110 99.86 Very High Very High Very High
Neurocysticercosis 30 99.12 Very High Very High Very High
Cough 5 98.84 Very High Very High Very High
Coma 13 98.72 Very High Very High Very High
Gauchers Disease 27 97.80 Very High Very High Very High
Lysosome Storage Disease 17 97.44 Very High Very High Very High
Stress 40 97.08 Very High Very High Very High
Disease 162 95.88 Very High Very High Very High
Neurological Disease 7 93.36 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
As an inhibitor of glucosylceramide synthase, eliglustat tartrate has been shown to be effective as both a monotherapy and in combination with ERT in a mouse model of Gaucher disease [18], [19].
Negative_regulation (inhibitor) of glucosylceramide synthase associated with gauchers disease
1) Confidence 0.25 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2991350 Disease Relevance 1.07 Pain Relevance 0.03
This can be achieved by inhibiting the enzyme glucosylceramide synthase which catalyzes the first step in the synthesis of glycosphingolipids (GL-1) and therefore subsequent molecules including GL-3.
Negative_regulation (inhibiting) of glucosylceramide synthase
2) Confidence 0.22 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2991350 Disease Relevance 0.71 Pain Relevance 0.03
The premise of SRT for Fabry disease using inhibitors of glucosylceramide synthase has been evaluated in mouse models [12]–[14] and shown to be of some benefit in lessening the burden of glycolipid accumulation.
Negative_regulation (inhibitors) of glucosylceramide synthase associated with fabry disease
3) Confidence 0.18 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2991350 Disease Relevance 0.75 Pain Relevance 0.03
Since glycolipid storage appears to contribute to at least some of the neuropathologic features, an iminosugar inhibitor of glucosylceramide synthase (miglustat, also known as N-butyl-deoxynojirimycin, NB-DNJ and OGT 918, later approved for substrate reduction therapy of mild to moderate type 1 Gaucher disease), was administered to npc1 mutant mice and cats.
Negative_regulation (inhibitor) of glucosylceramide synthase associated with gauchers disease
4) Confidence 0.08 Published 2010 Journal Orphanet J Rare Dis Section Body Doc Link PMC2902432 Disease Relevance 0.30 Pain Relevance 0
Thus, the constant release and persistence of parasite GCs during the course of NCC most likely leads to a suppressive and immunoregulatory environment that supports parasite establishment and maintenance while minimizing damaging inflammatory responses.
Negative_regulation (persistence) of GCs associated with inflammatory response and neurocysticercosis
5) Confidence 0.06 Published 2008 Journal PLoS Neglected Tropical Diseases Section Body Doc Link PMC2274955 Disease Relevance 1.15 Pain Relevance 0.24
It is also notable that the GCs migrating into the DB are strongly immunoreactive for COX, and so PGs synthesised by these cells could exert local paracrine effects in the decidua.
Negative_regulation (immunoreactive) of GCs in decidua
6) Confidence 0.06 Published 2007 Journal Placenta Section Body Doc Link PMC1895600 Disease Relevance 0.49 Pain Relevance 0.08
N-butyldeoxynojirimycin (NB-DNJ), an iminosugar analog, has been used as a glucosylceramide synthase inhibitor [26].
Negative_regulation (inhibitor) of glucosylceramide synthase
7) Confidence 0.05 Published 2010 Journal Current Chemical Genomics Section Body Doc Link PMC2995157 Disease Relevance 0.52 Pain Relevance 0
This approach involves the use of a glucosylceramide synthase inhibitor, which would slow the rate of Gb3 synthesis, and thus decrease lysosomal storage.
Negative_regulation (inhibitor) of glucosylceramide synthase associated with lysosome storage disease
8) Confidence 0.04 Published 2010 Journal Current Chemical Genomics Section Body Doc Link PMC2995157 Disease Relevance 0.62 Pain Relevance 0
First, based on the GCS and examination of brainstem reflexes, imminent brain death can be defined as: ‘A state in which a deeply comatose, mechanically ventilated patient, admitted to an ICU, with irreversible catastrophic brain damage of known origin (e.g.
Negative_regulation (defined) of GCS in brain associated with brain death, medulla and coma
9) Confidence 0.03 Published 2010 Journal Intensive Care Med Section Body Doc Link PMC2921050 Disease Relevance 1.03 Pain Relevance 0.49
The mean prehospital GCS was also found to be lower in the MMT-assisted group.
Negative_regulation (lower) of GCS
10) Confidence 0.01 Published 2010 Journal Langenbecks Arch Surg Section Body Doc Link PMC2908760 Disease Relevance 0.97 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox